A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 [choline-fenofibrate] in combination with atorvastatin and ezetemibe to atorvastatin in combination with ezetimibe in subjects with combined (atherogenic) dyslipidemia

Trial Profile

A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of ABT-335 [choline-fenofibrate] in combination with atorvastatin and ezetemibe to atorvastatin in combination with ezetimibe in subjects with combined (atherogenic) dyslipidemia

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2011

At a glance

  • Drugs Atorvastatin; Choline fenofibrate; Ezetimibe
  • Indications Dyslipidaemias
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 11 Dec 2008 Actual initiation date changed from Mar 2008 to Feb 2008 as reported by ClinicalTrials.gov.
    • 11 Dec 2008 Planned number of patients changed from 460 to 543 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top